文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

脓毒症微循环调控:血管活性药物对微循环血流影响的系统评价

Manipulating the Microcirculation in Sepsis - the Impact of Vasoactive Medications on Microcirculatory Blood Flow: A Systematic Review.
PubMed 文献 · Shock · 2019-01-01
一句话结论系统评价未发现任何单一药物能可重复改善脓毒症患者微循环血流或改善结局,现有证据等级多为低级别。

该系统评价纳入2000年1月至2018年2月发表的22项研究(6项随机对照试验、12项干预性研究、3项观察性研究、1项先导研究,共572例参与者),评估血管活性药物对脓毒症患者舌下微循环血流的影响。去甲肾上腺素未显示改善微循环血流(低级别证据,6项研究),仅在慢性高血压患者中例外(低级别,1项研究);去甲肾上腺素基础上加用精氨酸加压素或特利加压素可维持血流并减少去甲肾上腺素需求(高级别,2项研究);多巴酚丁胺和硝酸甘油均未一致改善血流(低级别,6项研究);单中心研究(40例)显示左西孟旦改善血流(高级别)。16/16项干预性、先导和观察性研究存在高偏倚风险。作者认为目前无稳健证据表明任一药物可可重复改善微循环血流,也无研究显示任一药物结局获益。

要点

  • 去甲肾上腺素未显示改善脓毒症微循环血流(低级别证据,6项研究),仅在慢性高血压患者中例外(低级别,1项研究)
  • 去甲肾上腺素基础上加用精氨酸加压素或特利加压素可维持微循环血流并减少去甲肾上腺素需求(高级别证据,2项研究)
  • 多巴酚丁胺和硝酸甘油均未一致改善微循环血流(低级别证据,6项研究)
  • 单中心40例研究显示左西孟旦改善微循环血流(高级别证据)
  • 16/16项干预性、先导和观察性研究存在高偏倚风险

适用人群与场景

  • 脓毒症患者(研究纳入标准为脓毒症患者,发表时间2000年1月至2018年2月)

研究设计与关键结果

  • 系统评价共筛选2606篇文章,纳入22项研究(6项随机对照试验、12项干预性研究、3项观察性研究、1项先导研究,共572例参与者)
  • 去甲肾上腺素未显示改善微循环血流(低级别证据,6项研究),仅在慢性高血压患者中例外(低级别证据,1项研究)
  • 去甲肾上腺素基础上加用精氨酸加压素或特利加压素可维持微循环血流并减少去甲肾上腺素需求(高级别证据,2项研究)
  • 多巴酚丁胺和硝酸甘油均未一致改善微循环血流(低级别证据,6项研究)
  • 单中心40例研究显示左西孟旦改善微循环血流(高级别证据)
  • 16/16项干预性、先导和观察性研究存在高偏倚风险
  • 无研究显示任一治疗药物相比另一药物有结局获益

证据类型、等级与局限

  • 证据类型:系统评价,采用GRADE分级
  • 纳入研究偏倚风险:16/16项干预性、先导和观察性研究为高偏倚风险
  • 局限:原文未报告局限性

对床旁实践的改变

  • 作者认为目前无稳健证据表明任一药物可可重复改善脓毒症微循环血流
  • 作者认为无研究显示任一治疗药物相比另一药物有结局获益
  • 作者建议更新共识指南以改善测量报告的可比性并减少偏倚,从而围绕单个药物效应进行有意义的比较

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Sepsis is life-threatening organ dysfunction because of a dysregulated host response to infection. Disturbed microvascular blood flow is associated with excess mortality and is a potential future target for interventions. This review addresses the evidence for pharmacological manipulation of the microcirculation in sepsis assessed by techniques that evaluate the sublingual microvasculature.

METHODS: Systematic review using a published protocol. Eligibility criteria were studies of septic patients published from January 2000 to February 2018. Interventions were drugs aimed at improving perfusion. Outcome was improvement in microvascular flow using orthogonal polarization spectral, sidestream dark field, or incident dark field imaging (Grades of Recommendation, Assessment, Development, and Evaluation criteria used).

RESULTS: Two thousand six hundred and six articles were screened and 22 included. (6 randomized controlled trials, 12 interventional, 3 observational, and 1 pilot, n = 572 participants). Multiple measurement techniques were described, including: automated analyses, subjective, and composite scoring systems. Norepinephrine was not found to improve microvascular flow (low-grade evidence, n = 6 studies); except in chronic hypertension (low, n = 1 study). Addition of arginine vasopressin or terlipressin to norepinephrine maintained flow while decreasing norepinephrine requirements (high, n = 2 studies). Neither dobutamine nor glyceryl trinitrate consistently improved flow (low, n = 6 studies). A single study (n = 40 participants) demonstrated improved flow with levosimendan (high). In a risk of bias assessment 16/16 interventional, pilot and observational studies were found to be high risk.

CONCLUSIONS: There is no robust evidence to date that any one agent can reproducibly lead to improved microvascular flow. Furthermore, no study demonstrated outcome benefit of one therapeutic agent over another. Updated consensus guidelines could improve comparable reporting of measurements and reduce bias, to enable meaningful comparisons around the effects of individual pharmacological agents.

来源:Shock,查看原文。版权归原作者所有。

参考来源

  1. Potter EK, Hodgson L, Creagh-Brown B, et al. Manipulating the Microcirculation in Sepsis - the Impact of Vasoactive Medications on Microcirculatory Blood Flow: A Systematic Review. Shock. 2019. PMID: 30102639. doi:10.1097/SHK.0000000000001239

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。